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Abstract
Bioneedles are small hollow sugar based needles administered with a simple compressed air device. In the present study we
investigate how incorporation of a subunit vaccine based on TB vaccine hybrid Ag85B-ESAT-6 adjuvated with CAF01 into
Bioneedles affects its immunogenicity as well as its ability to protect against TB in a mouse model. The CMI response
measured by IFN-c and antigen specific CD4+ T-cells was, two weeks after the last vaccination, significantly lower in the
group immunized with Bioneedle-incorporated vaccine compared to the conventional vaccine, using syringe and needle.
However, at four, nine and 52 weeks after vaccination we observed similar high IFN-c levels in the Bioneedle group and the
group vaccinated using syringe and needle and comparable levels of antigen specific T-cells. Furthermore, the protective
efficacy for the two vaccination methods was comparable and similar to BCG vaccination both six and 52 weeks after
vaccination. These results therefore advocate the further development of the Bioneedle devises and applicators for the
delivery of human vaccines.
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Introduction
Parenteral injection using needles and syringes is the most
common route of administration of vaccines today. However this
method possesses safety risks for patients and health care
providers. A recent publication showed e.g. that 72.6% of the
healthcare staff in Kabul hospitals reported sharps injuries over a
period of 12 months [1]. Consequently the number of infections
among health care professionals attributable to injuries from
needles and syringes are worldwide estimated to 66,000 hepatitis B
(HBV) incidences, 16,000 hepatitis C virus (HCV) incidences and
1,000 human immunodeficiency virus (HIV) incidences per year
[2]. Furthermore, improper vaccination practice, such as reuse of
needles and syringes are commonly found in the developing world,
resulting in an increased risk for pathogen transmission during
vaccination. In a comprehensive study conducted in Africa in
2000, WHO found that reuse of injection equipment in the
absence of sterilization, was only assumed to have zero risk in four
out of 14 regions. In the remaining 10 regions, WHO estimated
that 1.2% to 75% of the annual 1.7–11.3 injections per person
were administered with reused equipment causing an estimated 21
million HBV infections, two million HCV infections and 260 000
HIV infections [3].
With the high prevalence of diseases like HBV, HCV and HIV
in tuberculosis (TB) endemic regions it is of crucial importance to
consider safe delivery strategies when developing novel vaccines
against TB. Even though much effort has been devoted to
developing alternative administration techniques for vaccines,
there is still a need for a safe, effective needle free vaccine delivery
system, which at the same time is easy to distribute and handle
even in rural districts of the developing world, with lack of reliable
roads, refrigeration and educated personal. One potential
approach is transcutaneous immunization, with the vaccine being
delivered to the immune cells of the skin, usually by using a patch
for hydration and/or disruption of the stratum corneum allowing
penetration of the vaccine [4,5,6]. However, there is limited
experience about their applicability in the developing world,
where it can be more difficult to monitor compliance issues i.e.
that the patches are kept on for the appropriate amount of time
and that they are kept dry and clean. In order to obtain high
compliance it is in general a much more safe approach to apply a
vaccine in a manner that prevents the vaccinated in discontinuing
the immunization. This on the other hand relies on educated
personal and simple to handle devises which are easy to repair or
replace. Jet injectors delivering the vaccine to the intradermal,
subcutaneous or intramuscular cavities through high pressure
nozzles have been implemented with variable success in mass
immunization campaigns. A Hepatitis B outbreak in 1985 was
linked to the use of multi-use-nozzle jet injectors that were
contaminated by body fluids during vaccination, thereby causing a
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nozzle jet injectors and led to the development of new devises with
disposable caps [8] or single-use-nozzle devises [9]. A major draw-
back of these devises is that there is no international standard on
vaccine cartridges hindering the application of different devises for
the same vaccine, which for practical reasons usually only will be
filled in one type of containers. Another draw-back is that these
devises are often highly sophisticated electrical equipment, which
makes them inappropriate for use in the developing world.
An interesting new approach is to inject mini implants
containing the vaccine into the body using a low-tech compressed
air devise. One such technology is Bioneedles, which are small
hollow sugar based needles (Figure 1A) administered into the
muscle with a simple compressed air devise from an initial distance
of 3–10 mm from the skin surface, thereby avoiding cross
contamination of patients [10]. The wound at site of injection is
no bigger than that observed with an ordinary needle and since the
duration of the vaccination is only approximately 0.7 milliseconds,
faster than the time it takes to recognize pain, then the vaccine has
already been administered by the time the vaccinated realizes it,
practically abolishing the feeling of pain (van de Wijdeven;
publication in preparation). Bioneedles are prepared of polymers
which upon administration will be degraded by enzymes resulting
in a release of the vaccine. They do, however, not contain any
adjuvant effect making it necessary to combine the vaccine antigen
with an adjuvant to induce the appropriate immune response.
Bioneedles has previously been tested together with a AlPO4
adjuvated tetanus toxoid vaccine [11] in a mouse model. This
study showed that those injected with the vaccine in a bioneedle
obtained a functional antibody response comparable to the group
receiving the conventional liquid vaccine.
In the present study we investigate how incorporation of a
subunit vaccine based on adjuvated TB vaccine hybrid Ag85B-
ESAT-6 (H1) into Bioneedles affects its immunogenicity as well as
its ability to protect against TB in a mouse model. Numerous
studies have demonstrated a positive correlation between the
induction of a Th1 response and resistance to a subsequent
challenge with TB [12]. This excludes the use of any of the
adjuvants presently approved for human use all being Th2
inducers, whereas previous studies have shown that CAF01 (also
designated DDA/TDB) is capable of inducing protective Th1
immune responses against TB when combined with H1 [13,14].
H1 is currently in phase two clinical trials in combination with
IC31 adjuvant, as well as phase one clinical trials with the CAF01
adjuvant.
With the pros and cons related to the use of needles and syringes
in mind, we have to consider new vaccination concepts which can
fulfil the requirements to safety, stability, ease-of-application and
reliability. These aspects are of particular importance when
developing a new vaccine against TB and the Bioneedle
technology fulfils these criteria. The combination of a novel TB
vaccine with the Bioneedle delivery system, therefore offers a
unique modern vaccination concept. In the present study we
therefore investigated how incorporation of H1 and CAF01 into
Bioneedles affects the protective efficacy in mice as compared to a
similar vaccine injected with syringe and needle. We found, that
even though the immune response was altered, we still obtained
protective efficacy comparable to both the conventional vaccine
using syringe and needle and to the existing BCG vaccine.
Results and Discussion
Incorporation of the vaccine into Bioneedles resulted in a
delayed immune response as compared to the regular
vaccine
In this study, a panel of vaccines containing tuberculosis vaccine
antigen H1 alone or in combination with Bioneedle, CAF01 or
CAF01:Bioneedle was used for vaccination and the CMI response
Figure 1. Bioneedles are small hollow sugar based needles. A Bioneedle is pictured in A) next to a standard 0.5625 mm Terumo needle. B)
IFN-c responses in mice (pooled PBMCs) two weeks after the last of three immunizations with 2 mg of H1 antigen alone (light grey) or in Bioneedles
(dark grey), combined with CAF01 (black) or combined with CAF01 and incorporated in Bioneedles (white).
doi:10.1371/journal.pone.0015043.g001
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a two-week interval and blood samples were collected by
periorbital puncture at week 2, 4, 9 and 52 after the last
vaccination. The levels of IFN-c secretion were assessed by ELISA
analysis upon in vitro restimulation with H1. Vaccination with the
Ag alone or Ag:Bioneedle did not increase the immune response
against the antigen (Figure 1). These groups were therefore not
included in the long term memory and -protection studies.
At the early time point, two weeks after the last immunization,
incorporation of the adjuvated vaccine into the Bioneedle
(Ag:CAF01:Bioneedle) reduced the vaccine immunogenicity as
compared to the conventional vaccine (Ag:CAF01). This is
observed by a significant reduction of IFN-c cytokine production
of Ag:CAF01:Bioneedle as compared to Ag:CAF01 (Figure 1B).
This significant reduction was not observed after 4, 9 and 52
weeks which could be explained by a delayed release of the vaccine
from the Bioneedles giving an equally delayed immune response as
compared to regular vaccination (Figure 2). The endpoint data after
restimulation of spleenic cells obtained 52 weeks after vaccination
was comparable to those obtained in PBMCs (data not shown).
Bioneedle embedded vaccine resulted in altered fre-
quency of highly differentiated T-cells as compared to the
regular vaccine. The ability of TH1 cells to produce IFN-c has
been described as essential to drive an effector T-cell response,
whereas TNF-a and especially IL-2 are necessary for the additional
induction of a memory T-cell response [15,16]. The IFN-c results
described previously suggest that the magnitude of the vaccine
induced T-cell response observed in blood two weeks after
immunization is lower when administered in Bioneedles as
compared to the regular vaccine using syringe and needle. We
therefore characterized the phenotype and cytokine production of the
T-cells using intracellular flow cytometry staining after immunization
with H1 combined with either CAF01 or CAF01:Bioneedle. H1
specific CD44
high CD4 T cells were assessed for their cytokine
production to establish the proportion of CD4 cells expressing IFN-c,
TNF-a,a n dI L - 2 .T h eC D 4
+CD44
high T-cell population was
separated into seven distinct subpopulations based on their
production of IFN-c,I L - 2 ,o rT N F - a in any combination, and the
representation of each of these subpopulations within the pool of T
cells was established (Figure 3).
The CD4 T cells induced by CAF01 two weeks after the last
vaccination were primarily IFN-c+TNF-a+IL-2+ multifunctional
T cells and TNF-a+IL-2+ central memory T cells (,37% for each
subpopulation). The overall induction of IFN-c-, TNF-a and/or
IL-2 producing T-cells was reduced when using Bioneedles for
vaccination at this early timepoint after vaccination (Figure 3B).
This was especially the case for the highly differentiated IFN-
c+TNF-a+IL-2+ T-cells which only accounted for ,20% whereas
the less differentiated TNF-a+IL-2+ cell population made up
,50% of the total population. Two weeks later (week four post
vaccination) the overall T-cell frequency had waned a little for
both vaccine groups but the T-cell differentiation pattern was
similar to the previous results. An increase in the frequency of
IFN-c-, TNF-a and/or IL-2 producing T-cell was observed from
week 4 to week 52 post vaccination with both the Bioneedle
embedded and the regular vaccine. The increase was however
most pronounced in the CAF01:Bioneedle vaccinated animals,
where at least an 8-fold increase in the frequency of cytokine
producing T-cells was observed (Figure 3B). The multifunctional
cells that express TNF-a+IL-2+ double positive and IFN-c+TNF-
a+IL-2+ triple-positive cells dominated the responding T cell
population in both vaccination groups (Figure 3C). At all
timepoints, the responses in naive control mice were undetectable
(data not shown) regardless of the cytokine measured. CD8
responses were likewise evaluated but no CD8-specific responses
were observed in any of the groups. The endpoint data after
restimulation of spleenic cells obtained 52 weeks after vaccination
was comparable to those obtained in PBMCs (data not shown).
CAF01 has in previous studies been shown to form a vaccine
depot at site of injection [17]. This depot effect could very well be
even more pronounced with the condensation of the vaccine and
its incorporation into the Bioneedles, which could well explain the
increase in cytokine producing T-cells at the late time point after
vaccination with the Bioneedle embedded vaccine (Figure 3B).
Bioneedle embedded vaccine induced protection against
TB comparable to the regular vaccine and BCG. The ability
of the CAF01 adjuvated H1 vaccine delivered in Bioneedles to elicit
protection against M. tuberculosis was then evaluated and compared
to protection levels obtained with unvaccinated and BCG
vaccinated mice. The mice were challenged through the aerosol
route with M. tuberculosis Erdman. H1 in CAF01 and
CAF01:Bioneedles provided significant levels of protection in the
lungs (p,0.001) comparable to that offered by the standard BCG
vaccination with approximately one log reduction in bacterial
numbers (Figure 4A). As expected, vaccination with H1 alone or
delivered in Bioneedles, resulting in low levels of cell-mediated
immune responses, also failed to provide protection against TB. We
next assessed whether the memory CMI obtained after vaccination
with H1 combined with either CAF01 or CAF01:Bioneedle
(Figure 2 and 3) was translated into protective efficacy by
Figure 2. IFN-c responses in mice. The IFN-c responses were
measured upon restimulation of pooled PBMCs 2, 4, 9 and 52 weeks
after the last of three immunizations with 2 mg of H1 antigen combined
with CAF01 (black) or combined with CAF01 and incorporated in
Bioneedles (white). Values marked with an asterisk are significantly
different (***, p,0.001).
doi:10.1371/journal.pone.0015043.g002
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PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e15043Figure 3. An icFACS analysis of cytokine expression in CD4 T cells in mice. The cytokine expression pattern were measured upon
restimulation of pooled PBMCs 2, 4 and 52 weeks after the last of three immunizations with 2 mg of H1 antigen combined with CAF01 (black) or
combined with CAF01 and incorporated in Bioneedles (white). A) Gating tree for phenotypic and functional characterization of memory CD4 T cells in
H1:CAF01-immunized mice by multiparameter flow cytometry. Lymphocytes were gated based on their forward scatter (FSC) vs side scatter SSC
profile, and the CD4+CD44high. B) Intracellular IFN-c, TNF-a, and IL-2 levels expressed as geometric MFI values were compared within the
CD4+CD44high population. There were no significant difference between the MFI values obtained from the two vaccination groups. C) The cytokine-
producing cells were divided into seven distinct subpopulations based on their production of these cytokines in any combination. The bar chart
shows the frequency of each cytokine subset being CD44high out of the total CD4 T cell population. The bars within each subpopulation represent
the two vaccination methods at week two, four and 52 after vaccination (exemplified in the triple positive subpopulation).
doi:10.1371/journal.pone.0015043.g003
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vaccination the H1 in CAF01 and CAF01:Bioneedles were still able
to induce approximately half a log reduction in bacterial numbers,
which was comparable to that seen in age matched mice receiving
the live BCG vaccine six weeks prior to challenge (Figure 4B).
Furthermore, a slightly albeit not significant, increase in protection
was observed when administering H1 in CAF01:Bioneedles as
compared to CAF01, correlating with the increased amount of
memory T-cells obtained at this late timepoint.
These results therefore suggest that the administration of
H1:CAF01 TB vaccine in Bioneedles is at least as good if not
better at inducing protective long term memory against TB as the
same vaccine administered with needle and syringe as well as the
presently approved BCG vaccine. Combined with the advantages
regarding logistics (low sample weight and volume), no need for
preservatives, ease of use, low pain and – maybe most importantly
– that the method permits the administration without contacting
the skin, thus avoiding cross contamination between handlings
[10] advocate the further development of the Bioneedle devises
and applicators for the delivery of human vaccines.
Materials and Methods
All the necessary permits for this study were provided by the
Danish Ministry of Justice.
Materials
DDA (purity .99%) and TDB (purum .99%) were obtained
from Avanti Polar Lipids (Alabaster, AL). Methanol (extra pure),
chloroform (extra pure) and 1 M hydrochloric acid, used to adjust
pH in the Tris-buffer, were purchased from Merck (Darmstadt,
Germany). Tris base (99%) and cholesterol (purity $ 99%) were
obtained from Sigma-Aldrich Inc. (St. Louis, MO). Water for
injection (WFI) from Statens Serum Institut (Copenhagen, Den-
mark) was used to prepare the buffer.
Preparation of CAF01 liposomes
CAF01 was formulated by the thin film method as previously
described [18]. Weighed amounts of DDA and TDB were
dissolved in chloroform/methanol (9:1, by volume) and the
organic solvent was removed using a gentle stream of N2 forming
a thin lipid film on the bottom of the test tube. The lipid film was
dried over night to remove trace amounts of the organic solvent.
The lipid film was hydrated in 10 mM Tris-buffer at pH 7.4, to a
final concentration of 5.0 mg/ml DDA and 1.0 mg/ml TDB, by
heating for 20 min at 60uC with in-between whirl mixing.
Preparation of vaccine in Bioneedles
Bioneedles were produced according to Bioneedle Technologies
Group’s proprietary procedures using injection molding of
thermoplastic starch. In order to incorporate an entire mouse dose
of CAF01 (0.25 mg DDA +0.05 mg TDB) into the inside cavity of
the Bioneedles with a volume of about 4.0–4.6 ml it was necessary to
reduce the dose volume with a factor 12.5. This was done by
vacuum concentration for 10 minutes using a Heto Hetovac VR-1
andHeto CT110vacuumconcentrator followed by heating to60uC
for 5 minutes on a water bath and whirl mixing. This procedure was
repeated until the dose volume was 4.0 ml. 2 mg of the vaccine
antigen H1, produced as previously described [19], was added
before up-concentration. The concentrated vaccines were trans-
ferred to a 1 ml BD syringe for filling the Bioneedles. Bioneedles
containing 2 mg/dose of H1 was prepared for reference in the
immunization experiments. After filling, the Bioneedles were frozen
to 255uC on the temperature controlled shelf in a Christ ALPHA
Figure 4. TB bacterial burden in mice upon vaccination. Mice were challenged by the aerosol route with virulent M. tuberculosis A) 6 weeks
and B) 52 weeks after the last immunization. Six weeks post challenge, mice were sacrificed and the bacterial burden (CFU) measured in the lungs
(expressed as log10 CFU). As a positive control group, a group of mice received a BCG vaccination ten weeks before challenge.
doi:10.1371/journal.pone.0015043.g004
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followed by freeze drying. The primary drying was carried out
through 20 hours at 225uC and 4 mBar vacuum. The shelf
temperature was then gradually raised to +20uC over a period of
20 hours whilst in the same time decreasing pressure until 0.04
mbar. A final drying step was done at +20uC and 0.04 mBar for
6 hours. After filling and freeze-drying, the Bioneedles were
individually stored in vials, closing these under ambient air and
relative humidity, using rubber stoppers and aluminium caps.
Vaccination of mice
The study is build on two experiments: 1) a long term
immunogenicity experiment in which the mice were challenged
with TB 52 weeks after the last immunization and a short term TB
challenge study. Female C57BL/6 mice, 6–12 weeks old, obtained
from Harlan Scandinavia (Allerod, Denmark) were divided into
groups of eight for the investigation of immunogenicity and groups
of six for the short term TB challenge study. The mice receiving
the regular injections were immunized three times with a 2-week
interval, subcutaneously (s.c.) at the base of the tail with 0.2 ml
vaccine containing either 2 mg H1 alone or in combination with
CAF01 (0.25 mg DDA +0.05 mg TDB). The mice receiving the
Bioneedle vaccinations were immunized simultaneously with those
receiving the regular injections. The Bioneedles were injected in
the scruff of the neck using a disposable one-way implanter (Loligo
Systems, Tjele, Denmark). A group of BCG-vaccinated mice was
included in each TB challenge experiment as a control for vaccine
efficacy. These mice received 5610
6 CFU of BCG Danish 1331
s.c. in 0.2 ml of 0.9% saline at the same time that the remaining
test groups received their first immunization with experimental
subunit vaccines. No booster injections were given to the BCG
group. All experiments were conducted in accordance with the
regulations of the Danish Ministry of Justice and animal protection
committees (Permit no. 2004/561-868) and in compliance with
European Community Directive 86/609.
Immunogenicity assays
Enzyme-linked immunosorbent assay (ELISA). Blood was
obtained by periorbital puncture and the peripheral blood
mononuclear cells (PBMCs) were purified as previously described
[20]. All cell cultures were performed in microtitre plates (Nunc,
Roskilde, Denmark) containing 2610
5 cells in a volume of 200 ml
RPMI-1640 supplemented with 5610
5 M 2-mercaptoethanol, 1 mM
glutamine, 1% pyruvate, 1% penicillin–streptomycin, 1% HEPES,
and 10% fetal calf serum (all from Gibco Invitrogen, Carlsbad,
Denmark). PBMCs isolated two, four and 52 weeks post vaccination
were stimulated with H1-antigen at a concentration of 0.5 mg/ml.
Wells containing medium only or 5 mg/ml concanavalin A were used
as negative and positive controls, respectively. Culture supernatants
were harvested after 72 hr incubation and the amounts of IFN-c were
determined by ELISA as previously described [21].
Intracellular flow cytometric analysis (icFACS). PBMCs
isolated two, four and 52 weeks post vaccination were stimulated
with 5 mg/ml H1 for 1 h in the presence of 1 mg/ml anti-CD28
(clone 37.51) and anti-CD49d (clone 9C10 (MFR4.B); both from
BD Pharmingen) and subsequently incubated for 5–6 h at 37uC
following the addition of 10 mg/well brefeldin A (Sigma-Aldrich)
and 0.7 ml/well monensin/GolgiStop (BD Pharmingen). Following
overnight storage at 4uC, cells were washed in FACS buffer (PBS
containing 0.1% sodium azide and 1% FCS), and subsequently
stained for 30 min at 4uC for surface markers with mAbs as
indicated using 1/200 dilutions of anti-CD4-allophycocyanin-Cy7
(clone GK1.5), anti-CD8-PerCP-Cy5.5 (clone 53-6.7), and anti-
CD44-FITC (clone IM7) (all BD Pharmingen). Cells were then
washed inFACSbuffer,permeabilized using the Cytofix/Cytoperm
kit (BD Pharmingen) according to the manufacturer’s instructions,
and stained intracellularly for 30 min at 4uC in dilutions of 1/100
using anti-IFN-c-PE-Cy7 (clone XMG1.2; eBioscience), anti-TNF-
a-PE (clone MP6-XT22; BD Pharmingen), or anti-IL-2-
allophycocyanin (clone JES6-5H4; BD Pharmingen) mAbs. Cells
were subsequently washed, resuspended in FACS buffer, and then
analyzed using a six-colour BD FACSCanto flow cytometer (BD
Biosciences).Finally,responseswereanalyzed usingFlowJosoftware
version 8.7 (Mac) followed by Pestle and Spice (Tree Star).
TB challenge of mice
M. tuberculosis Erdman for infection was grown in suspension in
modified Sauton medium enriched with 0.5% sodium pyruvate,
0.5% glucose and 0.02% Tween 80 [20]. Challenge infections with
M. tuberculosis were administered six or 52 weeks after the last
immunization, by the aerosol route in a Glas-Col inhalation
exposure system (Glas-Col, Terre Haute, IN) with an inoculum of
,25 CFU per mouse. The mice were sacrificed after six weeks of
challenge infection, and bacterial numbers in the lungs were
determined by macerating the organs and plating serial threefold
titrations on Middlebrook 7H11 agar plates. Organs from BCG-
vaccinated mice were grown on 7H11 plates supplemented with
2 mg of 2-thiophenecarboxylic acid hydrazide per ml to selectively
inhibit the growth of BCG. After 2 weeks of incubation at 37uC,
the numbers of bacteria were counted and reported in CFU. All
results are based on individual analyses of five to six mice per
group.
Statistical analysis
For comparative analysis of immunogenicity, data were tested
by one-way analyzes of variance (ANOVA). When significant
differences were indicated, differences between means were
determined by Bonferroni’s multiple comparison test. All statistical
analyses were performed in GraphPad Prism version 5 (GraphPad
Software Inc., La Jolla, CA).
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